Baseline cardiovascular characteristics and post-infusion events in patients undergoing CAR-T cell therapy
Clicks: 1
ID: 323314
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #112 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Introduction CAR-T cell therapy has significantly advanced the treatment of hematologic malignancies. Cardiovascular complications have been reported, particularly in patients with pre-existing risk factors or cardiovascular disease. Baseline cardiovascular profiles and post-infusion events in real-world practice remain limited. Objective To describe baseline cardiovascular characteristics and the incidence of cardiovascular events after CAR-T therapy in a single-centre cohort. Materials and Methods This prospective, descriptive, non-interventional study included consecutive patients treated with CAR-T between 2019 and 2025. Baseline evaluation included epidemiological data, cardiovascular risk factors, history of cardiovascular disease, SCORE2 risk stratification, and assessment in a cardio-oncology consultation. Baseline imaging (echocardiography and cardiac magnetic resonance) was collected. Patients were followed for cytokine release syndrome (CRS) and cardiovascular events. Descriptive statistics were performed using SPSS v27. Results 236 patients were included (mean age 59 ± 11 years, 61% male). Most patients were treated for lymphoma or multiple myeloma, while a small proportion had other hematologic malignancies. 86% had ≥1 cardiovascular risk factor, 25% had prior cardiovascular disease, and 42% were high or very high risk by SCORE2. Baseline cardio-oncology evaluation identified new cardiovascular diagnoses in 36% of patients and prompted therapy adjustments in 30%, optimizing cardiovascular status prior to CAR-T infusion. CRS occurred in 93% of patients, ≥grade 2 in 31%, mainly early, with a median onset of 3 days (range 0–12). Hypotension was the most frequent cardiovascular manifestation. During follow-up, 16% experienced ≥1 clinically relevant cardiovascular event, most commonly acute heart failure (7%) and atrial fibrillation (4%), with a median time to first event of 144 days. Overall mortality was 31%, mainly due to disease progression, with no deaths attributable to cardiovascular causes. Conclusions CAR-T-treated patients showed high prevalence of cardiovascular risk factors and history of cardiovascular disease, with a notable incidence of post-infusion cardiovascular events. These findings highlight the importance of comprehensive baseline assessment and close follow-up within cardio-oncology units.Table 1 Table 2
| Reference Key |
openalex_W7172276404
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | B Aumente Rodriguez, L Moreno De Redrojo Cortes, A C Martin-Garcia, S Rodriguez Diego, E Iglesias Colino, E Perez Lopez, A A Martin Lopez, R Eiros Bachiller, M Garcia Lopez, C Alvarez Martinez, A Serna Fernandez, D Clavo Martin, P L Sanchez Fernandez, L Lopez Corral, A C Martin-Garcia |
| Journal | European heart journal supplements : journal of the European Society of Cardiology |
| Year | 2026 |
| DOI |
10.1093/eurheartjsupp/suag097.074
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.